Cumulative incidence and incidence rates of HZ during the study.¹Cumulative follow-up period is the sum of follow-up periods censored at the occurrence of HZ, relapse, or death. Patients were followed from V1 to study end (June of 2020). ²One participant was excluded from the TVC because an episode of HZ occurred before V1. ³Participants who developed HZ <30 days from V2. Participants excluded from the mTVC include 8 patients who did not receive V2, 4 patients who relapsed before V2, and 1 patient who had HZ prior to 30 days after V2. ⁴The median follow-up time at risk was 157 days (IQR, 84-237) in the mTVC. Eleven patients did not reach 30 days at risk, including 7 patients without follow-up after V2, 2 patients with <30 days follow-up after V2, and 2 patients with relapse at <30 days follow-up after V2.